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Visualizing type IV endoleak using magnetic
resonance imaging with a blood pool
contrast agent
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Growing evidence suggests that graft porosity hampers aneurysm shrinkage in patients who have been treated with
the original Excluder device. To our knowledge, this suspected porosity has never been visualized in such patients.
We present three patients treated with the original Excluder device whose aneurysms did not shrink in the first 2
years after treatment. Computed tomography (CT) angiography and late phase CT did not show endoleak. We
performed late phase magnetic resonance imaging with a blood pool agent to visualize graft porosity. Our cases
illustrate the usability of a new contrast agent and a new imaging strategy for visualizing slow-flow endoleaks that
can not be imaged using currently used imaging techniques with conventional contrast agents. ( J Vasc Surg 2008;
47:861-4.)Aneurysms which shrink after endovascular aneu-
rysm repair (EVAR) have been successfully treated. The
cause of endotension, aneurysm growth without en-
doleak, and stable aneurysm size in the absence of en-
doleak is still unclear.1 It is likely that in such cases the
aneurysm sac remains perfused or at least pressurized.
One possible explanation is that endoleak is present, but
not visualized by computed tomography angiography
(CTA). Magnetic resonance (MR) based techniques may
be used to further explore the role of endoleak in these
cases.
Magnetic resonance imaging with use of conven-
tional Gd-based contrast agent visualizes more en-
doleaks 2-4 and allows for more accurate endoleak classi-
fication than CTA.5 One class of endoleak, which has
until now only been suspected but has not yet been
visualized, is leakage due to graft porosity of the original
Excluder device (W.L. Gore, Inc, Flagstaff, Ariz) pre-
sumably causing the low shrinkage rates associated with
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doi:10.1016/j.jvs.2007.09.073this device.6,7 We present three patients after EVAR with
such an endoprosthesis in whom routine follow-up im-
aging with CTA demonstrated nonshrinking aneurysms
without evidence of endoleak. In these patients, graft
porosity was visualized using a new MR contrast agent, a
T1-shortening blood pool agent, in combination with
late phase magnetic resonance imaging. These cases
demonstrate a new way of imaging endoleaks that re-
mained elusive with use of CTA.
CASE REPORT
From June to November 2006, three patients treated
with an original Excluder endoprosthesis presented at
the outpatient clinic with a nonshrinking aneurysm with-
out endoleak on CTA and delayed phase CT. CT scans
had been performed as part of the clinical follow-up
protocol on a 64-slice scanner during injection of 36 g
iodine (Iopromide 300 mg/mL; Schering, Berlin, Ger-
many) at 1.8 g/s. Delayed phase CT was performed 90
seconds after injection. Clinical information about the
patients is presented in the Table. According to our
clinical protocol, aneurysm size change was evaluated on
the CTA examinations by diameter measurements. The
patients were asked to undergo one additional MR ex-
amination. The study was approved by the institutional
review board and written informed consent was obtained
from the participants. During the MR-examination, a
new contrast agent was used: Gadofosveset trisodium
(Vasovist, Bayer Schering Pharma, Berlin, Germany).
This agent is gadolinium-based and binds to albumin,
through which it remains longer intravascular than cur-
rently used MR and CT-contrast agents.8 Three sets of
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April 2008862 Cornelissen et alT1-weighted spin echo images (TR/TE/ 580 ms/15
ms/90°, slice thickness 3.0 mm, FOV 270  385 mm2,
acquisition matrix 179  256, 60 slices, NSA  1,
acquisition time 5 minutes 27 seconds) were acquired,
Fig. Transverse T1-weighted spin echo MR- images, the
postcontrast, and the third row the late phase postcontrast
same patient and the same anatomical location. In the last
and (I). Arrowheads point to endoleak.
Table. Clinical information of patients
Patient no Age(y)/sex Initial EVAR date Initial AA
1 82/M July 2004 5
2 80/M Aug 2003 5
3 58/M Jan 2004 6
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; Ccovering the area of the aortic endoprosthesis. The firstset was acquired before injection, the second early after
contrast injection (3 to 10 minutes), and the third late
after contrast injection (30 minutes). Both sets of
postcontrast images were compared with the precontrast
ow shows the precontrast, the second row the early phase
eighted images. Each column consists of images from the
endoleak arising from graft porosity is visible in (C), (F),
meter
Diameter of AAA in follow-up CT
scan/date
Interval
CT – MRI (d)
58/June2006 15
57/Aug 2006 26
64/Nov2006 45
mputed tomography; MRI, magnetic resonance imaging.first r
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2images to detect endoleaks. In all three patients, contrast
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phase postcontrast images, which was not present on the
precontrast images or on the early phase postcontrast
images. This is illustrated in the figure, in which slices
through the endoleak are shown next to each other. The
leaks we visualized were confined to the direct vicinity of
the endoprosthesis and seemed connected to the pros-
thesis lumen, without a visible connection to a branching
artery. For this reason, the endoleaks were classified as
graft porosity.
DISCUSSION
Our report presents a new imaging method to visualize
endograft porosity which could until now not be visualized.
Endoleaks due to porosity of the graft material (type IV
endoleak) most probably remained occult in CTA examina-
tions because of the small delay between contrast agent injec-
tion and imaging.
To facilitate the detection of slow-flow endoleaks, dif-
ferent timings of delayed CT images with respect to con-
trast agent injection have been advocated, varying from 60
seconds to 130 seconds after injection.9-11 However, due
to a rapid decrease in contrast agent concentration in the
blood after injection of extracellular contrast agents, the
contrast between blood and surrounding tissue decreases
rapidly with time after injection. For magnetic resonance
imaging (MRI), recently a blood pool agent became avail-
able, which remains longer intravascular than currently
used contrast agents. By using such an agent in combina-
tion with T1-weighted MRI, the delay between injection
and imaging can be extended allowing for the accumula-
tion of a higher amount of contrast agent in the endoleak
while maintaining adequate contrast between blood and
surrounding tissue.
The use of a blood pool agent for the detection of
endoleak has been reported before. In that study, the
iron-oxide based blood pool agent ferumoxytol was used.12
In that study, none of the included patients had the original
Excluder endograft. No endoleaks originating from graft
porosity were visualized.
For visualizing type IV endoleaks we acquired two sets
of postcontrast images, early postcontrast images 3 to 10
minutes after injection and late postcontrast images, 30 to
70 minutes after injection. Although such a long delay
between injection and imaging is clinically rather impracti-
cal, it was necessary for accurate detection of these type IV
endoleaks. In these patients, the early postcontrast images
did not lead to endoleak detection. We do not know
whether the long delay of 30 minutes was necessary. A less
time-consuming protocol for detection of type IV en-
doleaks may result from the continuous acquisition of scans
until 30 minutes after contrast injection. Scanning can then
be stopped earlier when a leak is visualized. However, such
an approach is less comfortable for the patients than a
30-minute break.
A potential weakness of the comparison between CTA
andMRI in these patients is the time between the CTA and
the MRI examinations. Due to logistical reasons, 15 to 45days elapsed between the two examinations. In theory, the
endoleak status of the patient could have changed during
this time. However, we think graft porosity is more a
chronic problem and will essentially not change in such a
short time span.
Recent literature suggests graft porosity to be present
only in the nonoverlapping parts of the original Excluder
endoprosthesis, where only one layer of ePTFE is
present.13 Comparison of the regions of endoleak on the
MR-images with the CTA-images demonstrated that in
two patients, the region of endoleak corresponded to the
region where no overlapping components of the endograft
were present. In the third patient, however, leakage was
present in the region of nonoverlapping graft components
but in fewer slices than expected; for unknown reasons, a
large region of nonoverlapping endograft was present that
did not show porosity.
The presented cases illustrate that the extended delay
between injection and imaging enabled us to visualize graft
porosity. Furthermore, this imaging strategy probably en-
ables us to visualize slow-flow endoleaks originating from
other sources. The longer intravascular half-life of such
agents may also allow for the visualization of intermittent
endoleak. All these types of endoleaks can keep the aneu-
rysm sac pressurized.
In conclusion, this technique is probably well suited to
provide explanations for certain cases of endotension. In
such cases, treatment of slow-flow endoleaks or intermit-
tent endoleaks, which can be identified with this imaging
technique, might stop aneurysm growth.
CONCLUSION
To our knowledge, in this study, graft porosity was
visualized in vivo through MR imaging using a blood
pool contrast agent for the first time. However, this
technique has a much wider application. It can serve as a
new strategy for investigating endotension. The role of
endoleak in such cases can be more precisely investigated
than in the past, possibly leading to endovascular treat-
ment alternatives for patients diagnosed with endoten-
sion by conventional methods without the use of blood
pool agents.
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